Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

R. Van Leeuwaarde
, F. Spada
, W. Cheung
, A. Gonzalez-Clavijo
, M. Pracht
, G. Emelianova
, C. Thirlwell
, K. Oberg

Department of Endocrine Oncology

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	122-122
Journal	Neuroendocrinology
Volume	106
Publication status	Published - 2018

Keywords

quality of life
gep-net
eortc qlq-ginet21

Cite this

@article{b175875a28164e508ce702f7dbb731f0,

title = "Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?",

keywords = "quality of life, gep-net, eortc qlq-ginet21",

author = "\{Van Leeuwaarde\}, R. and F. Spada and W. Cheung and A. Gonzalez-Clavijo and M. Pracht and G. Emelianova and C. Thirlwell and K. Oberg",

year = "2018",

language = "English",

volume = "106",

pages = "122--122",

journal = "Neuroendocrinology",

issn = "0028-3835",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

AU - Van Leeuwaarde, R.

AU - Spada, F.

AU - Cheung, W.

AU - Gonzalez-Clavijo, A.

AU - Pracht, M.

AU - Emelianova, G.

AU - Thirlwell, C.

AU - Oberg, K.

PY - 2018

Y1 - 2018

KW - quality of life

KW - gep-net

KW - eortc qlq-ginet21

M3 - Meeting Abstract

SN - 0028-3835

VL - 106

SP - 122

EP - 122

JO - Neuroendocrinology

JF - Neuroendocrinology

ER -